The effect of melatonin supplementation with progesterone on the improvement and level of inflammatory factors in patients with endometrial hyperplasia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220116053735N1

Enrollment

Registered

2022-06-19

Start date

2022-03-20

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperplasia. Persistent hyperplasia of thymus

Interventions

Intervention 1: Intervention group: Two medroxyprogesterone 5 mg tablets (manufactured by Caspian) and two 10 mg melatonin tablets (manufactured by Galenus) are given every night from the fifteenth da

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with endometrial atypical hyperplasia, without a history of treatment, referred to the clinic of Beheshti Hospital in Kashan,

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

Measure	Time frame
One consequence of the study is the lack of observation of hyperplastic lesions in pathology examination and report of secondary pathology. Another consequence is an increase in the levels of the above inflammatory factors in re-testing by ELISA at the end of the fourth month of treatment. Timepoint: monthly. Method of measurement: In this study, interviews and observations and researcher-made checklists were used.	—

Measure

Time frame

One consequence of the study is the lack of observation of hyperplastic lesions in pathology examination and report of secondary pathology. Another consequence is an increase in the levels of the above inflammatory factors in re-testing by ELISA at the end of the fourth month of treatment. Timepoint: monthly. Method of measurement: In this study, interviews and observations and researcher-made checklists were used.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNeda Aslany

Kashan University of Medical Sciences

aslany-n@Kaums.ac.ir+98 916 290 7375

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026